KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Goodwill & Intangibles: 2021-2024

Historic Goodwill & Intangibles for Regeneron Pharmaceuticals (REGN) over the last 4 years, with Dec 2024 value amounting to $1.1 billion.

  • Regeneron Pharmaceuticals' Goodwill & Intangibles rose 23.28% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year increase of 23.28%. This contributed to the annual value of $1.1 billion for FY2024, which is 10.59% up from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Goodwill & Intangibles stood at $1.1 billion for FY2024, which was up 10.59% from $1.0 billion recorded in FY2023.
  • Regeneron Pharmaceuticals' 5-year Goodwill & Intangibles high stood at $1.1 billion for FY2024, and its period low was $6.7 million during FY2021.
  • Over the past 3 years, Regeneron Pharmaceuticals' median Goodwill & Intangibles value was $1.0 billion (recorded in 2023), while the average stood at $1.0 billion.
  • Data for Regeneron Pharmaceuticals' Goodwill & Intangibles shows a peak YoY soared of 13,564.18% (in 2022) over the last 5 years.
  • Regeneron Pharmaceuticals' Goodwill & Intangibles (Yearly) stood at $6.7 million in 2021, then surged by 13,564.18% to $915.5 million in 2022, then rose by 13.45% to $1.0 billion in 2023, then grew by 10.59% to $1.1 billion in 2024.